Stock Update (NASDAQ:VVUS) Climbs as its erectile dysfunction trial meets goals

If you are planning to invest money in stock market then you must subscribe to FREE Alerts by visiting: http://www.pennystockpickreport.com/

VIVUS, Inc. (NASDAQ:VVUS) soared 6.42% to $9.12 after The erectile dysfunction drug being developed by Vivus Inc (VVUS.O) met the goals of a Phase 3 trial, and was shown to be effective in 30 minutes or less, the company said on Wednesday.

The 646-patient late-stage trial found that about three-quarters of patients taking either a 100 mg or a 200 mg dose of the drug, avanafil, had erections sufficient for intercourse. Fifty-seven percent experienced "successful intercourse," compared with 27 percent of placebo patients.

VIVUS, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets.

ABOUT http://www.pennystockpickreport.com/
 
 Penny Stock Pick Report is one of the leading stock web site which provides free stock news alerts and newsletter. We also track small cap penny stocks, daily penny stocks to watch that could be on the brink of a massive breakout. You can contact us if  you wish to get your company featured on our website .